Research Topics
Species | Dan ZieglerSummaryAffiliation: Heinrich Heine University Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Evaluation of the Neuropad sudomotor function test as a screening tool for polyneuropathy in the elderly population with diabetes and pre-diabetes: the KORA F4 surveyD Ziegler
Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Leibniz Center for Diabetes Research, Dusseldorf, Germany
Diabetes Metab Res Rev 28:692-7. 2012..This study aimed to evaluate the utility of Neuropad as a screening tool for distal symmetric polyneuropathy among elderly subjects with diabetes and pre-diabetes in the general population...
High sensitive troponin T and heart fatty acid binding protein: novel biomarker in heart failure with normal ejection fraction? A cross-sectional studyWilfried Dinh
Department of Cardiology, Witten Herdecke University, HELIOS Klinikum Wuppertal, Germany
BMC Cardiovasc Disord 11:41. 2011..We tested whether hsTnT and hFABP plasma levels are elevated in patients with heart failure with normal ejection fraction (HFnEF)...- Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction RegistryDan Ziegler
Institute of Clinical Diabetes Research, German Diabetes Center, Leibniz Center for Diabetes Research at the Heinrich Heine University, Dusseldorf, Germany
Eur J Pain 13:582-7. 2009..Associated cardiovascular risk factors including abdominal obesity and low physical activity may constitute targets to prevent neuropathic pain in this population... - Treatment of diabetic neuropathy and neuropathic pain: how far have we come?Dan Ziegler
Institute for Clinical Diabetes Research, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, Dusseldorf, Germany
Diabetes Care 31:S255-61. 2008.... 
Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort StudyDan Ziegler
Institute for Clinical Diabetes Research, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, Dusseldorf, Germany
Diabetes Care 31:556-61. 2008..To evaluate whether reduced heart rate variability (HRV), prolonged corrected QT (QTc) interval, or increased QT dispersion (QTD) are predictors of mortality in the general diabetic and nondiabetic population...- Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3Dan Ziegler
Institute for Clinical Diabetes Research, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, Dusseldorf, Germany
Diabetes Care 31:464-9. 2008..The aim of this study was to determine the prevalence and risk factors of polyneuropathy in subjects with diabetes, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or normal glucose tolerance (NGT)... - [Treatment of diabetic neuropathy]D Ziegler
, Deutsches Diabetes-Zentrum,
Dtsch Med Wochenschr 132:1043-7. 2007 - Type 2 diabetes as an inflammatory cardiovascular disorderD Ziegler
German Diabetes Clinic, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, WHO Collaborating Center in Diabetes, European Training Center in Endocrinology and Metabolism, Dusseldorf, Germany
Curr Mol Med 5:309-22. 2005..Drugs exerting anti-inflammatory and vascular effects have future potential to be used within an array of interventions aimed at reducing the enormous cardiovascular burden associated with Type 2 diabetes... - [Duloxetine, a new therapeutic option for diabetic peripheral neuropathic pain]D Ziegler
Deutsche Diabetes Klinik, Deutsches Diabetes Zentrum, Leibniz Zentrum an der Heinrich Heine Universität Düsseldorf, Dusseldorf, Germany
Dtsch Med Wochenschr 131:S284-8. 2006..The various drugs should be considered individually in any treatment algorithm, also taking into account their side effects. Psychotherapeutic methods serve to support the overcoming of pain... - Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general populationD Ziegler
German Diabetes Clinic, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, WHO Collaborating Center in Diabetes, European Training Center in Endocrinology and Metabolism, Dusseldorf, Germany
Exp Clin Endocrinol Diabetes 114:153-9. 2006..However, obesity and smoking contribute to autonomic dysfunction in men but not women. Thus, a selectivity and sex-related differences exist among the various cardiovascular risk factors as to their influence on autonomic dysfunction... - Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic painDan Ziegler
German Diabetes Center, Leibniz Institute at the Heinrich Heine University, 40225 Dusseldorf, Germany
Diabetes Care 30:664-9. 2007..To evaluate the impact of baseline disease variables related to diabetes and diabetic neuropathy severity on efficacy and safety of duloxetine in the management of diabetic peripheral neuropathic pain... - Treatment of diabetic polyneuropathy: Update 2006Dan Ziegler
German Diabetes Clinic, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, WHO Collaborating Center in Diabetes, European Training Center in Endocrinology and Metabolism, Dusseldorf, Germany
Ann N Y Acad Sci 1084:250-66. 2006.... - Management of painful diabetic neuropathy: what is new or in the pipeline for 2007?Dan Ziegler
Institut für Klinische Diabetologie, Deutsches Diabetes Zentrum, Leibniz Zentrum an der Heinrich Heine Universität Düsseldorf, 40225 Dusseldorf, Germany
Curr Diab Rep 7:409-15. 2007..Among at least 50 new drugs for treatment of neuropathic pain in the pipelines, there are several promising candidates such as lacosamide. Individual tolerability remains a major aspect in any treatment decision... - Painful diabetic neuropathy: treatment and future aspectsDan Ziegler
Institute of Clinical Diabetes Research, German Diabetes Center, Leibniz Center at the Heinrich Heine University, Dusseldorf, Germany
Diabetes Metab Res Rev 24:S52-7. 2008..In future, drug combinations might also include those aimed at symptomatic pain relief and quality of life on one hand and improvement or slowing the progression of the underlying neuropathic process on the other hand... - Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trialDan Ziegler
Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Germany
Diabetes Care 34:2054-60. 2011..Primary end point was a composite score (Neuropathy Impairment Score [NIS]-Lower Limbs [NIS-LL] and seven neurophysiologic tests). Secondary outcome measures included NIS, NIS-LL, nerve conduction, and quantitative sensory tests (QSTs)... - Neuropad: evaluation of three cut-off points of sudomotor dysfunction for early detection of polyneuropathy in recently diagnosed diabetesD Ziegler
Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Leibniz Center for Diabetes Research, Dusseldorf, Germany
Diabet Med 28:1412-5. 2011..To examine the sensitivity and specificity of three cut-off points of Neuropad for the diagnosis of distal symmetric polyneuropathy and small-fibre dysfunction in patients within the first year after diagnosis of diabetes... - Current concepts in the management of diabetic polyneuropathyDan Ziegler
Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Dusseldorf, Germany
Curr Diabetes Rev 7:208-20. 2011.... - Efficacy and safety of lacosamide in painful diabetic neuropathyDan Ziegler
nstitute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Leibniz Center for Diabetes Research, and the Department of Metabolic Diseases, University Hospital, Dusseldorf, Germany
Diabetes Care 33:839-41. 2010..To evaluate efficacy and safety of lacosamide compared with placebo in painful diabetic polyneuropathy... - Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patientsDan Ziegler
Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Leibniz Center for Diabetes Research, and Department of Metabolic Diseases, University Hospital, Dusseldorf, Germany
Diabetes Care 32:1479-84. 2009..CONCLUSIONS Sequential intravenous and oral actovegin treatment over 160 days improved neuropathic symptoms, VPT, sensory function, and quality of life in type 2 diabetic patients with symptomatic polyneuropathy... - Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3Dan Ziegler
Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, Dusseldorf, Germany
Pain Med 10:393-400. 2009..The aim of this study was to determine the prevalence and risk factors of neuropathic pain in subjects with diabetes, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or normal glucose tolerance (NGT)... - Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trialDan Ziegler
FRCPE, Deutsche Diabetes Klinik, Deutsches Diabetes Zentrum, Leibniz Institut an der Heinrich Heine Universität, Auf m Hennekamp 65, 40225 Dusseldorf, Germany
Diabetes Care 29:2365-70. 2006..The aim of this trial was to evaluate the effects of alpha-lipoic acid (ALA) on positive sensory symptoms and neuropathic deficits in diabetic patients with distal symmetric polyneuropathy (DSP)... - Subclinical inflammation and diabetic polyneuropathy: MONICA/KORA Survey F3 (Augsburg, Germany)Christian Herder
Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany
Diabetes Care 32:680-2. 2009..Therefore, we investigated whether circulating concentrations of acute-phase proteins, cytokines, and chemokines differ among diabetic patients with or without diabetic polyneuropathy... - Prediabetic neuropathy: does it exist?Nikolaos Papanas
Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Leibniz Center for Diabetes Research, Dusseldorf, Germany
Curr Diab Rep 12:376-83. 2012..In practice, therapy of prediabetic neuropathy should be addressed towards normoglycemia and correction of cardiovascular risk factors. However, additional work is needed to establish the long-term results of this approach... - Postchallenge hyperglycemia is positively associated with diabetic polyneuropathy: the KORA F4 studyBrenda W C Bongaerts
Heinrich Heine University Dusseldorf, Dusseldorf, Germany
Diabetes Care 35:1891-3. 2012..To assess the prevalence of distal sensorimotor polyneuropathy (DSPN) in an older population and to examine its relationship with prediabetes... - Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routineR Freynhagen
Department of Anaesthesiology, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
Int J Clin Pract 61:1989-96. 2007..We aimed to investigate pregabalin, a gamma-aminobutyric acid (GABA)-analogue, in a wide range of pregabalin naive patients with treatment refractory NeP... - Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysisD Ziegler
German Diabetes Research Institute, Leibriz Institute at the Heinrich Heine University, Dusseldorf, Germany
Diabet Med 21:114-21. 2004..To determine the efficacy and safety of 600 mg of alpha-lipoic acid given intravenously over 3 weeks in diabetic patients with symptomatic polyneuropathy... - Application of isotope-selective nondispersive infrared spectrometry (IRIS) for evaluation of [13C]octanoic acid gastric-emptying breath tests: comparison with isotope ratio-mass spectrometry (IRMS)P Schadewaldt
Diabetes Forschungsinstitut, Klinische Biochemie Auf m Hennekamp 65, Dusseldorf, Germany
Clin Chem 43:518-22. 1997..99x + 4.06, Sy[symbol: see text]x = +/- 6.3; tlag, breath: y = 0.97x + 0.96, Sy[symbol: see text]x = +/-3.4; GEC: y = 0.97x - 0.01, Sy[symbol: see text]x = +/-0.09)... - Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic NeuropathyD Ziegler
Diabetes Forschungsinstitut an der Heinrich Heine Universität, Dusseldorf, Germany
Diabetes Care 22:1296-301. 1999..To evaluate the efficacy and safety of alpha-lipoic acid given intravenously, followed by oral treatment in type 2 diabetic patients with symptomatic polyneuropathy... - Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trialsD Ziegler
Diabetes Forschungsinstitut an der Heinrich Heine Universität, Dusseldorf, Germany
Exp Clin Endocrinol Diabetes 107:421-30. 1999.... - Normal ranges and reproducibility of statistical, geometric, frequency domain, and non-linear measures of 24-hour heart rate variabilityD Ziegler
Klinische Abteilung, Deutsches Diabetes Forschungsinstitut an der Heinrich Heine Universität, Dusseldorf, Germany
Horm Metab Res 31:672-9. 1999..The majority of the HRV measures, in particular the geometric parameters, show a relatively high intraindividual reproducibility which underlines their suitability for the use in prospective studies... - Management of erectile dysfunction in diabetic patientsD Ziegler
German Diabetes Research Institute, Heinrich Heine University, , Germany
Diabetes Nutr Metab 15:58-65. 2002 - Diagnosis and treatment of diabetic autonomic neuropathyD Ziegler
German Diabetes Research Institute, Heinrich Heine University, German Diabetes Clinic, Auf m Hennekamp 65, Dusseldorf 40225, Germany
Curr Diab Rep 1:216-27. 2001..Prior to an adequate symptomatic treatment a thorough risk-benefit estimate, aimed at maintaining the patient's quality of life, is required... - [Autonomic neuropathies in diabetic patients. Heart involvement signals poor prognosis]D Ziegler
,
MMW Fortschr Med 144:35-7. 2002 - Immune mediators in patients with acute diabetic foot syndromeChristian Weigelt
Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Dusseldorf, Germany
Diabetes Care 32:1491-6. 2009..Further studies should investigate whether an activation of the immune system precedes the development of foot ulcer and whether anti-inflammatory therapies might be effective... - Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical reviewDan Ziegler
German Diabetes Clinic, German Diabetes Research Institute, Leibniz Institute at the Heinrich Heine University, Dusseldorf, Germany
Treat Endocrinol 3:173-89. 2004.... - Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathyDan Ziegler
German Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany
Diabetes Care 27:2178-83. 2004..The objective of this study was to evaluate plasma levels of various biomarkers of oxidative stress in diabetic subjects in relation to the presence or absence of polyneuropathy (PN) and/or cardiovascular autonomic neuropathy (CAN)... - Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responsesD Ziegler
Diabetes Research Institute, Heinrich Heine University, Dusseldorf, Germany
Diabet Med 9:166-75. 1992.... - Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulationL Reichstein
German Diabetes Clinic, German Diabetes Center, Leibniz Institute, , Auf'm Hennekamp 65, , Germany
Diabetologia 48:824-8. 2005..External muscle stimulation offers a new therapeutic option for DSP... - Validation of a novel screening device (NeuroQuick) for quantitative assessment of small nerve fiber dysfunction as an early feature of diabetic polyneuropathyDan Ziegler
Deutsche Diabetes Klinik, Deutsches Diabetes Zentrum, Leibniz Zentrum an der Heinrich Heine Universität, Auf m Hennekamp 65, 40225 Dusseldorf, Germany
Diabetes Care 28:1169-74. 2005..To validate a handheld screening device (NeuroQuick) for an early detection of diabetic distal symmetric polyneuropathy (DSP) by quantitative testing of cold sensation based on the wind chill factor (NeuroQuick threshold [NQT])... - Clinical trials for drugs against diabetic neuropathy: can we combine scientific needs with clinical practicalities?Dan Ziegler
German Diabetes Research Institute at the Heinrich Heine University, German Diabetes Clinic, 40225 Dusseldorf, Germany
Int Rev Neurobiol 50:431-63. 2002.... - Impact of diabetic polyneuropathy and cardiovascular autonomic neuropathy on the excretion of urinary 8-epi-PGF2alpha and its metabolites (2, 3-dinor and 2, 3-dinor-5, 6-dihydro)Jaffar Nourooz-Zadeh
Department of Medicine, Royal Free and University College London School of Medicine, London, UK
Free Radic Res 40:723-9. 2006..48; P < 0.001). In conclusion, these biomarkers should prove useful in studies evaluating the impact of therapeutic drugs or antioxidant interventions aimed at delaying the onset of diabetic complications... - Diabetic cardiovascular autonomic neuropathyAaron I Vinik
Strelitz Diabetes Research Institute, 855 W Brambleton Avenue, Norfolk, VA 23510, USA
Circulation 115:387-97. 2007 - Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicityPeter J Dyck
Peripheral Neuropathy Research Laboratories, Mayo Clinic College of Medicine, 200 First St, SW, Rochester, MN 55905, USA
Diabetes Care 30:2619-25. 2007..Assessing clinimetric performance of diabetic sensorimotor polyneuropathy (DSPN) end points in single and multicenter trials... - New perspectives on the management of diabetic peripheral neuropathic painTroels S Jensen
Department of Endocrinology, Diabetology and Nutrition, Hôpital Jean Verdier APHP Paris Nord University, Bondy, France
Diab Vasc Dis Res 3:108-19. 2006..Irrespective of which treatment is offered, only about one third of patients are likely to achieve more than 50% pain relief. Further research to improve the diagnosis and management of DPNP is needed... - The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trialAlexander S Ametov
Russian Medical Academy for Advanced Studies, Moscow, Russia
Diabetes Care 26:770-6. 2003..Because of its safety profile and its effect on positive neuropathic sensory symptoms and other neuropathic end points, this drug appears to be a useful ancillary treatment for the symptoms of diabetic polyneuropathy... - Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studiesDaniel K Kajdasz
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
Clin Ther 29:2536-46. 2007.... - Diabetic neuropathies: a statement by the American Diabetes AssociationAndrew J M Boulton
Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, U.K
Diabetes Care 28:956-62. 2005 - Diabetic autonomic neuropathy. Cardiac sympathetic "dysinnervation," QT interval prolongation, and mortalityDan Ziegler
Clin Auton Res 12:349-52. 2002 - Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunctionDan Ziegler
Deutsche Diabetes-Klinik, Deutsches-Diabetes-Zentrum, Leibniz-Institut, , , Germany
J Sex Med 3:883-91. 2006..CONCLUSION: These data suggest that vardenafil significantly improves erectile function in men with type 1 diabetes and is well tolerated, regardless of the level of glycemic control... - Polyneuropathy in the diabetic patient--update on pathogenesis and managementDan Ziegler
Nephrol Dial Transplant 19:2170-5. 2004 - Stroke in patients with diabetes mellitusBoris N Mankovsky
Institute of Endocrinology, Kiev, Ukraine
Diabetes Metab Res Rev 20:268-87. 2004..Aggressive control of arterial hypertension and dyslipidemia allows to decrease the risk of stroke in diabetic patients substantially, while the importance of glucose control for stroke prevention remains unproven...